quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:14·756d
SECFiling
CymaBay Therapeutics Inc. logo

SEC Form EFFECT filed by CymaBay Therapeutics Inc.

CBAY· CymaBay Therapeutics Inc.
Health Care
Original source

Companies

  • CBAY
    CymaBay Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 13UpdateRaymond James-
  • Aug 14UpdateUBS$18.00
  • Aug 11UpdateGuggenheim$20.00
  • Apr 5UpdateWilliam Blair-
  • Mar 9UpdateBTIG Research$15.00
  • Apr 11UpdateCantor Fitzgerald$9.00

Related

  • PR379d
    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
  • FDA617d
    FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC
  • SEC753d
    SEC Form 15-12G filed by CymaBay Therapeutics Inc.
  • SEC756d
    SEC Form EFFECT filed by CymaBay Therapeutics Inc.
  • SEC756d
    SEC Form EFFECT filed by CymaBay Therapeutics Inc.
  • SEC756d
    SEC Form EFFECT filed by CymaBay Therapeutics Inc.
  • SEC756d
    SEC Form EFFECT filed by CymaBay Therapeutics Inc.
  • INSIDER762d
    SEC Form 4 filed by Loewy Caroline M
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022